Sight Sciences (NASDAQ:SGHT) EVP Brenton Taylor Sells 2,869 Shares

Sight Sciences, Inc. (NASDAQ:SGHT) EVP Brenton Taylor sold 2,869 shares of the stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $3.70, for a total transaction of $10,615.30. Following the sale, the executive vice president owned 267,807 shares of the company’s stock, valued at $990,885.90. This trade represents a 1.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Brenton Taylor also recently made the following trade(s):

• On Tuesday, January 6th, Brenton Taylor sold 619 shares of Sight Sciences stock. The shares were sold at an average price of $7.48, for a total value of $4,630.12.

Sight Sciences Price Performance

SGHT opened at $3.52 on Friday. The business has a 50 day moving average price of $4.82 and a two-hundred day moving average price of $5.73. The company has a quick ratio of 9.52, a current ratio of 10.22 and a debt-to-equity ratio of 0.63. The company has a market cap of $190.12 million, a PE ratio of -4.69 and a beta of 2.50. Sight Sciences, Inc. has a 52 week low of $2.03 and a 52 week high of $9.24.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Wednesday, March 4th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.07. The company had revenue of $20.39 million for the quarter, compared to the consensus estimate of $20.35 million. Sight Sciences had a negative return on equity of 55.72% and a negative net margin of 49.67%. As a group, research analysts anticipate that Sight Sciences, Inc. will post -0.99 EPS for the current year.

Wall Street Analysts Forecast Growth

SGHT has been the topic of several recent research reports. Piper Sandler set a $9.00 price objective on shares of Sight Sciences in a research note on Monday, January 5th. UBS Group reduced their target price on shares of Sight Sciences from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, March 6th. Citigroup lowered their target price on shares of Sight Sciences from $9.10 to $6.50 and set a “neutral” rating on the stock in a report on Friday, March 6th. Raymond James Financial set a $9.00 price target on shares of Sight Sciences in a research note on Monday, January 5th. Finally, William Blair reissued an “outperform” rating on shares of Sight Sciences in a report on Thursday, March 5th. Five investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $8.31.

Institutional Investors Weigh In On Sight Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of SGHT. BNP Paribas Financial Markets boosted its stake in shares of Sight Sciences by 99.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,579 shares of the company’s stock worth $26,000 after acquiring an additional 3,785 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in Sight Sciences by 32.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 11,665 shares of the company’s stock valued at $48,000 after purchasing an additional 2,875 shares in the last quarter. R Squared Ltd purchased a new position in Sight Sciences in the 3rd quarter valued at approximately $64,000. XTX Topco Ltd acquired a new position in Sight Sciences during the second quarter worth $67,000. Finally, O Shaughnessy Asset Management LLC acquired a new position in Sight Sciences during the fourth quarter worth $81,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company’s flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye’s natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.